Drugs / Quadrivalent RIV with H3 strain 2 and adjuvant
Quadrivalent RIV with H3 strain 2 and adjuvant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04451954 | Jul 2020 → Sep 2021 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent RIV with H3 strain 2 and adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04451954 ↗ |
| Modality | Vaccine | “Recombinant Influenza Vaccine” NCT04451954 ↗ |
| Route | Intramuscular | “Route of administration: Intramuscular” NCT04451954 ↗ |